Results 11 to 20 of about 7,431,159 (264)

Drug-drug-gene interactions and adverse drug reactions. [PDF]

Pharmacogenomics J, 2020
The economic and health burden caused by adverse drug reactions has increased dramatically in the last few years. This is likely to be mediated by increasing polypharmacy, which increases the likelihood for drug–drug interactions.
Malki MA, Pearson ER.
europepmc   +5 more sources

DGIdb 2.0: mining clinically relevant drug-gene interactions. [PDF]

Nucleic Acids Res, 2016
The Drug–Gene Interaction Database (DGIdb, www.dgidb.org) is a web resource that consolidates disparate data sources describing drug–gene interactions and gene druggability.
Wagner AH, Coffman AC, Ainscough BJ, Spies NC, Skidmore ZL, Campbell KM, Krysiak K, Pan D, McMichael JF, Eldred JM, Walker JR, Wilson RK, Mardis ER, Griffith M, Griffith OL.   +14 more
europepmc   +5 more sources

CYP2D6 drug-gene and drug-drug-gene interactions among patients prescribed pharmacogenetically actionable opioids. [PDF]

Appl Nurs Res, 2017
Purpose When codeine and tramadol are used for pain management, it is imperative that nurses are able to assess for potential drug-gene and drug-drug-gene interactions that could adversely impact drug metabolism and ultimately pain relief. Both drugs are
Knisely MR, Carpenter JS, Draucker CB, Skaar T, Broome ME, Holmes AM, Von Ah D.   +6 more
europepmc   +5 more sources

Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services. [PDF]

Clin Transl Sci, 2023
Understanding patterns of drug‐gene interactions (DGIs) is important for advancing the clinical implementation of pharmacogenetics (PGx) into routine practice.
Pasternak AL, Ward K, Irwin M, Okerberg C, Hayes D, Fritsche L, Zoellner S, Virzi J, Choe HM, Ellingrod V.   +9 more
europepmc   +2 more sources

Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.

JAMA, 2022
Importance Selecting effective antidepressants for the treatment of major depressive disorder (MDD) is an imprecise practice, with remission rates of about 30% at the initial treatment.
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, PRIME Care Research Group, Aslam M, Batki SL, Bjork JM, Blow FC, Brenner LA, Chen P, Desai S, Dieperink EW, Fears SC, Fuller MA, Goodman CS, Graham DP, Haas GL, Hamner MB, Helstrom AW, Hurley RA, Icardi MS, Jurjus GJ, Kilbourne AM, Kreyenbuhl J, Lache DJ, Lieske SP, Lynch JA, Meyer LJ, Montalvo C, Muralidhar S, Ostacher MJ, Paschall GY, Pfeiffer PN, Prieto S, Przygodzki RM, Ranganathan M, Rodriguez-Suarez MM, Roggenkamp H, Schichman SA, Schneeweis JS, Simonetti JA, Steinhauer SR, Suppes T, Umbert MA, Vassy JL, Voora D, Wiechers IR, Wood AE.   +57 more
europepmc   +2 more sources

Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report. [PDF]

BMC Psychiatry, 2022
Background Response to antidepressant therapy is highly variable among individuals. Pharmacogenomic (PGx) testing presents an opportunity to guide drug selection while optimizing therapy outcomes and/or decreasing the risk for toxicity. Case presentation
Del Toro-Pagán NM, Matos A, Bardolia C, Michaud V, Turgeon J, Amin NS.   +5 more
europepmc   +2 more sources

Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6‐Mediated Drug–Drug–Gene Interactions of Venlafaxine in Koreans [PDF]

Clinical and Translational Science
CYP2D6‐mediated drug–drug–gene interactions (DDGIs) are known to influence the pharmacokinetics of venlafaxine and its metabolism to O‐desmethylvenlafaxine.
Sungyeun Bae, Ga‐Yeong Lee, Eunsol Yang, Woori Chae, Kyung‐Sang Yu, Joo‐Youn Cho, Anhye Kim, Namyi Gu, SeungHwan Lee   +8 more
doaj   +2 more sources

AI-based prediction of drug-gene interactions modulating tight junction integrity: A deep learning framework highlighting multiple therapeutic targets. [PDF]

J Oral Biol Craniofac Res
Introduction Tight junctions regulate epithelial and endothelial barrier function, and their dysfunction is linked to diseases such as inflammatory bowel disease, asthma, and cancer.
Keskar V, Shenoy A, Desai S.
europepmc   +2 more sources

Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. [PDF]

Drug Saf, 2021
Simvastatin has previously been associated with drug-induced interstitial lung disease. In this retrospective observational study, cases with non-specific interstitial pneumonia (NSIP) or idiopathic pulmonary fibrosis (IPF) with simvastatin-associated ...
Jessurun NT, Drent M, Wijnen PA, Harmsze AM, van Puijenbroek EP, Bekers O, Bast A.   +6 more
europepmc   +2 more sources

Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals. [PDF]

Front Pharmacol, 2022
Introduction: Minority groups are underrepresented in pharmacogenomics (PGx) research. Recent sub-analysis of CYP-GUIDES showed reduced length of stay (LOS) in depressed patients with CYP2D6 sub-functional status.
Crutchley RD, Keuler N.
europepmc   +2 more sources